Strata Critical Medical Inc Dossier
Qualitative Analysis
Business overview
Strata Critical Medical, Inc. (formerly known as Blade Air Mobility, Inc.) is a leading time-critical logistics and specialized clinical services provider to the United States healthcare industry. Following its strategic pivot in August 2025, which involved divesting its passenger division to Joby Aviation and acquiring Keystone Perfusion (ProFusion), the company rebranded as Strata Critical Medical (NASDAQ: SRTA). Strata operates as a vertically integrated, full-service organ transplant solutions company. Its operations are divided into two primary segments: Logistics (air and ground transportation of human organs, transplant teams, and organ placement services) and Clinical (surgical organ recovery, normothermic regional perfusion (NRP), preservation services, and other clinical services like cardiac perfusion staffing and equipment rentals).
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding clinical services (surgical organ recovery, normothermic regional perfusion, and preservation) to complement core logistics, capturing higher-margin clinical economics.
Expected impact: Aims to double organic Adjusted EBITDA by 2029 through a high-teens compound annual growth rate.
Operating as an open platform capable of transporting and supporting any FDA-approved machine perfusion device (e.g., TransMedics OCS, OrganOx, XVIVO) rather than pushing proprietary hardware.
Expected impact: Protects the company from device obsolescence risk and aggregates volume across all device manufacturers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Fits existing customer base in Kentucky and Ohio, establishing a strategic stronghold in the Midwest and Southern US, and expands the national footprint of staff and equipment available to support organ transplant customers.
Financial impact: Expected to generate approximately $10 million in revenue and $3 million in Adjusted EBITDA for the full year 2026.
Regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania, aligning with the company's bolt-on M&A strategy.
Financial impact: Expected to contribute approximately $100,000 of Adjusted EBITDA for the remainder of 2026.
Strategic Partnerships
Following the sale of its passenger division to Joby Aviation in August 2025, Strata positioned Joby as its preferred partner for future electric Vertical Takeoff and Landing (eVTOL) operations for medical transport.
Terms: Includes up to $35 million of contingent consideration (earn-out payments) from the passenger sale transaction payable over the next year.